Answers are grounded in this paper and cite their sources.
Objectives Portal vein (PV) stenting has emerged as a treatment for malignant PV obstruction with the potential to improve symptoms of portal hypertension. However, data on outcomes and optimal antithrombotic management remain limited. Methods We conducted a retrospective multicentre study including patients treated with PV stenting for malignant obstruction at two tertiary centres in the Netherlands. The study outcomes included technical and radiological success, complications, number of reinterventions, survival and stent patency. Antithrombotic regimens were recorded descriptively. Results A total of 54 patients with malignant PV obstruction were included, most commonly due to pancreatic carcinoma (57.4%) and biliary tract cancer (33.3%). The technical success rate was 94.4%. Procedure-related complications occurred in 9.6% of patients and included vascular perforation, bleeding and unintended catheterisation of adjacent vessels. Median overall survival was 8.5 months (95% CI 6.4 to 11.1) with an estimated 1-year survival rate of 30.8% (95% CI 20.0% to 47.4%). At 6 and 12 months, the cumulative incidence of stent occlusion was 27.6% (95% CI 15.1% to 40.1%) and 38.5% (95% CI 24.6% to 52.4%), corresponding to patency rates of 72.4% and 61.5%, respectively. Antithrombotic treatment regimens varied considerably between patients. Conclusions PV stenting for malignant obstruction is technically feasible with a high success rate and acceptable safety profile in a palliative setting. However, procedural complications do occur and antithrombotic management is highly variable. Further prospective studies are needed to optimise postprocedural management and evaluate its impact on stent patency and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Holster et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: